Alexander Nichols
President chez ENGENE HOLDINGS INC.
Profil
Alexander Nichols was the founder of Mythic Therapeutics, Inc. (founded in 2017) where he held the title of President, Chief Executive Officer & Director.
He is currently the President & Chief Operating Officer at enGene Holdings, Inc. (since 2023) and at enGene, Inc. (since 2022).
Previously, he worked as a Principal at QD Vision, Inc. and as an Associate at Flagship Pioneering.
Dr. Nichols completed his undergraduate degree at Oberlin College in 2008 and holds a doctorate from Harvard University.
Postes actifs de Alexander Nichols
| Sociétés | Poste | Début |
|---|---|---|
| ENGENE HOLDINGS INC. | President | 01/11/2023 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | President | 01/12/2022 |
Anciens postes connus de Alexander Nichols
| Sociétés | Poste | Fin |
|---|---|---|
QD Vision, Inc.
 QD Vision, Inc. Electrical ProductsProducer Manufacturing QD Vision, Inc. develops nanotechnology-based optical products for display and solid state lighting applications. Its materials and components are used to illuminate applications, including flat panel displays, solid state lighting systems, and defense and security projects. The company was founded by Jonathan S. Steckel, Joe J. Caruso, Seth Coe-Sullivan, Gregory V. Moeller and Vladimir Bulovic in 2004 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Mythic Therapeutics, Inc.
 Mythic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mythic Therapeutics, Inc. engages in the development of cancer therapeutics. The company was founded on June 6, 2018 and is headquartered in Waltham, MA. | Fondateur | - |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Analyste en capital-investissement | - |
Formation de Alexander Nichols
| Harvard University | Doctorate Degree |
| Oberlin College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENGENE HOLDINGS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
QD Vision, Inc.
QD Vision, Inc. Electrical ProductsProducer Manufacturing QD Vision, Inc. develops nanotechnology-based optical products for display and solid state lighting applications. Its materials and components are used to illuminate applications, including flat panel displays, solid state lighting systems, and defense and security projects. The company was founded by Jonathan S. Steckel, Joe J. Caruso, Seth Coe-Sullivan, Gregory V. Moeller and Vladimir Bulovic in 2004 and is headquartered in Lexington, MA. | Producer Manufacturing |
Mythic Therapeutics, Inc.
Mythic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mythic Therapeutics, Inc. engages in the development of cancer therapeutics. The company was founded on June 6, 2018 and is headquartered in Waltham, MA. | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
